Table 2 Basic characteristics of included trials
Eyes | Follow-up | pre SE | ||||
|---|---|---|---|---|---|---|
Artisan | Artiflex | Artisan | Artiflex | Artisan | Artiflex | |
Hedayatfar et.al(2017) [7] | 16 | 56 | 1w,1 m,3 m,6 m,12 m | −16.64 ± 6.83 | −10.33 ± 3.15 | |
Parsipour et.al(2016) [4] | 24 | 33 | 12 m | −10.39 ± 8.43 | − 10.39 ± 2.29 | |
Aerts et.al(2015) [8] | 371 | 257 | 17 ± 7.2(6 m, 1y, 2y) | −12.7 ± 5.0 | −9.29 ± 2.8 | |
Karimian et.al(2014) [9] | 40 | 36 | 30 ± 11 m | −11.6 ± 3.7 | −9.59 ± 1.97 | |
Alio et.al(2013) [10] | 16 | 15 | NR | −13.38 ± 4.33 | −11.32 ± 3.10 | |
Shin et.al.(2013) [11] | 40 | 36 | 3 m | −9.88 ± 2.19 | −7.67 ± 1.92 | |
Torri et.al (2013) [12] | 23 | 30 | 6 m | −11.84 ± 4.9 | − 9.78 ± 3.2 | |
Peris-Martinez et.al(2009) [13] | 12 | 18 | 12 m | −9.2 ± 2.6 | − 9.6 ± 2.6 | |
Kohnen et.al(2008) [14] | 15 | 15 | 6, 12 m | −10.23 ± 1.92 | −8.78 ± 1.56 | |
Tahzib et.al(2008) [15] | 22 | 27 | 1w, 1 m, 3 m, 12 m | −9.9 ± 2.74 | −9.95 ± 1.43 | |
Coullet et.al (2006) [5] | 31 | 31 | 12 m | −10.3 ± 3.2 | −9.5 ± 2.2 | |